EHR-embedded OCDT in Breast or GI Cancer

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

November 23, 2021

Study Completion Date

November 23, 2021

Conditions
Oral Cancer Directed TherapyBreast CancerGastrointestinal CancerOral Chemotherapy
Interventions
OTHER

Active Care Team Alert

"2\) Active care team alert via office practice nurse monitoring of ePRO oral responses scored at 3, indicating moderate-severe (grade ≥3) toxicity.~Office practice nurses will monitor ePRO oral responses and respond to those scored at 3 per disease center symptom management protocol.~The ePRO oral responses from the remaining participants will additionally be monitored by office practice nurses who will respond to ePRO responses with scores of 3, indicating a moderate-severe toxicity (grade 3 or higher)."

OTHER

Passive Care Team Alert

"Primary care teams are assigned an EHR inBasket pool through which PP messages are delivered. Providers will be responsible for reviewing ePRO responses via inBasket, selecting mark as reviewed button as mandated for all clinical messages within 48 hours per policy."

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT03858712 - EHR-embedded OCDT in Breast or GI Cancer | Biotech Hunter | Biotech Hunter